Neurodegenerative disorders (NDDs) affect over nine million Europeans and constitute a large economic burden to society. NDD biomarkers have transformed the research landscape by linking diseases to pathological processes and assisting drug development. NDD biomarkers improve the accuracy of diagnosis and prognosis with the use of non-invasive tools. However, their implementation in clinical practice is hampered by a lack of standardisation. This project will build on the knowledge and experience of EMPIR projects 15HLT04 NeuroMet, 18HLT09 NeuroMET2 and 18HLT10 CardioMet and the International Federation of Clinical Chemistry (IFCC) programme to standardise biomarker measurements, harmonise measurements across assay manufacturers as well as develop and implement new biomarkers.